Amgen co-founder William K. Bowes Jr. stands watch over the Thousand Oaks campus. Call it Amgen’s competition conundrum. Biosimilar drugs are a new class of medicine that Amgen could develop and reap great rewards but the Thousand Oaks-based biotech giant also could lose billions of dollars if competitors develop biosimilars for Amgen’s blockbuster drugs. Biosimilars…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
